MedTrace Logo

Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.

NCT02233322 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-11-14

No results posted yet for this study

Summary

The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed legs in children) or bone pain and weakness in adults. This study is to test whether or not giving iron helps correct the high FGF23 and there by correcting the phosphate problem.

Conditions

  • Autosomal Dominant Hypophosphatemic Rickets

Interventions

DIETARY_SUPPLEMENT

Iron

All subjects will receive iron supplementation based on iron levels in the blood

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Michael Econs, M.D. · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2019-11-12
Completion
2019-11-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233322 on ClinicalTrials.gov